Accessibility Menu
Novozymes A/s logo

Novozymes A/s(OTC) NVZMF

Market Cap$30.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+134%
5 Year-7%
1 Year-2%
1 Month+1%
$64.65
+1.07%
+0.69Today
Novozymes A/s last closing stock price
MetricPriceDate
Last closeUSD 64.652026-08-14
Novozymes A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.81%USD 63.502026-08-07
1 month+1.41%USD 63.752026-07-15
3 month+9.1%USD 59.262026-05-15
Year to date+4.75%USD 61.722025-12-30
1 year-2.32%USD 66.192025-08-12
3 year+43.04%USD 45.202023-08-11
5 year-7.06%USD 69.562021-08-13
Since inception+134.07%USD 27.622003-06-27

Novozymes A/s Financials at a Glance

Market Cap

$30.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€4.20B

Net Income (TTM)

€596.54M

EPS (TTM)

$1.48

P/E Ratio

43.51

Dividend

$1.01

Beta (Volatility)

0.17 (Low)

Price

$64.65

Volume

604

Open

$64.65

Previous Close

$64.65

Daily Range

$64.65 - $64.65

52-Week Range

$52.10 - $67.50

Estimated Earnings Date

Aug 20, 2026

NVZMF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novozymes A/s

Novozymes A/S is a leading provider of biological solutions, specializing in industrial enzymes, microorganisms, and probiotics. Established in 1925 and headquartered in Bagsvaerd, Denmark, the company serves diverse sectors globally, including food and beverage, agriculture, and household care.

Products and Services
  • Industrial enzymes for food and beverage applications
  • Microorganisms and probiotics for agriculture and animal health
  • Biological solutions for household care and industrial processing
Growth Outlook
  • Revenue growth of 12% year-over-year in Q1 2026
  • Strong demand for sustainable solutions driving market expansion
  • Investment in R&D to enhance product offerings and innovation
Financial Highlights
  • Q1 2026 net income of €199 million, reflecting a 10% increase
  • TTM revenue of €4.4 billion, with a gross profit margin of 54.3%
  • Dividend yield of 1.53%, indicating consistent shareholder returns
Novozymes A/S has established itself as a key player in the specialty chemicals industry, focusing on sustainable solutions that cater to various sectors. The company's commitment to innovation is evident in its robust R&D investments, which aim to enhance product offerings and meet the growing demand for environmentally friendly solutions. Recent financial performance highlights a strong revenue growth trajectory, with a notable increase in net income, showcasing the company's resilience and operational efficiency. The consistent dividend yield further underscores Novozymes' dedication to delivering value to shareholders. With a diverse product portfolio and a strategic focus on sustainability, Novozymes A/S presents a compelling opportunity for potential investors interested in the evolving landscape of biological solutions.
AI Generated • Aug 15, 2026

Industry

Chemicals

Sector

Materials

Employees

11,641

CEO

Ester Baiget, MBA

Website

www.novonesis.com

Headquarters

Lyngby, ND 2880, DK

NVZMF Financials

Key Financial Metrics (TTM)

Gross Margin

54.33%

Operating Margin

20.85%

Net Income Margin

14.21%

Return on Equity

5.52%

Return on Capital

6.37%

Return on Assets

3.61%

Earnings Yield

2.30%

Dividend Yield

1.56%

Payout Ratio

1.12%

Stock Overview

Market Cap

$30.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

466.23M

Volume

604

Avg. Volume

1.50K

Financials (TTM)

Gross Profit

€2.28B

Operating Income

€836.74M

EBITDA

€1.38B

Operating Cash Flow

€1.28B

Capital Expenditure

-€497.00M

Free Cash Flow

€784.54M

Cash & ST Invst.

€329.76M

Total Debt

€3.22B

Novozymes A/s Performance Analysis

Novozymes A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 2,479,729,1234.4%
20232023-12-31EUR 2,597,085,2684.7%
20242024-12-31EUR 4,146,661,51459.7%
20252025-12-31EUR 4,692,175,68713.2%
Novozymes A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-5.5%
Q32025-09-304.3%
Q42025-12-31-6.2%
Q12026-03-3112.4%
Novozymes A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 1.864.4%
20232023-12-31EUR 1.58-15.2%
20242024-12-31EUR 0.72-54.4%
20252025-12-31EUR 1.4195.7%
Novozymes A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-27.5%
Q32025-09-303.4%
Q42025-12-31-13.3%
Q12026-03-3165.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€1.12B

+4.0%

Gross Profit

€634.75M

+6.8%

Gross Margin

56.66%

N/A

Market Cap

$30.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.59M

N/A

Employees

11,641

N/A

Net Income

€199.27M

+7.1%

EBITDA

€418.46M

+1.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€329.76M

+28.6%

Total Debt

€3.22B

+89.3%

Accounts Receivable

€924.61M

+5.3%

Inventory

€793.57M

+8.7%

Long Term Debt

€2.93B

+130.6%

Short Term Debt

€289.42M

-32.7%

Return on Assets

3.61%

N/A

Return on Invested Capital

5.72%

N/A

Free Cash Flow

€74.00M

+44.5%

Operating Cash Flow

€167.10M

+57.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PPGPPG Industries, Inc.
$114.11-0.54%
AKZOYAkzo Nobel N.V.
$24.08+0.25%
SXYAYSika AG
$23.46-0.17%
SKFOFSika AG
$234.98+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About NVZMF

What is the current price of Novozymes A/s?

Novozymes A/s is trading at $64.65 per share.

What is the 52-week range for Novozymes A/s?

Over the past 52 weeks, Novozymes A/s has traded between $52.10 and $67.50.

How much debt does Novozymes A/s have?

As of the most recent reporting period, Novozymes A/s reported total debt of €3.70B.

How much cash does Novozymes A/s have on hand?

Novozymes A/s reported €377.00M in cash and cash equivalents in its most recent financial results.

What is Novozymes A/s’s dividend yield?

Novozymes A/s currently has a dividend yield of 1.56%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services